Last month, the FTC voted unanimously to examine rising list prices of insulin, but also to probe possible anti-competitive practices by PBMs. Proof of the establishment of anti-competitive practices - such as rebate walls - would likely lead to legal action being taken against PBMs.
Subscribe to:
Post Comments (Atom)
< + > Access Healthcare Builds Deep Client Relationships to Improve RCM
In our recent interview at the AHIMA Annual conference, Sid Mehta, President & Chief Growth Officer at Access Healthcare , discusses the...
No comments:
Post a Comment